Taylor Wessing has acted as legal advisor to the biopharmaceutical company Allecra Therapeutics in a further staged financing round. With this financing, Allecra Therapeutics primarily intends to carry out a Phase III study on the candidate drug AAI101, an antibiotic to combat multi-resistant bacteria which predominantly appear in hospitals.

The financing round was led by the venture capital investor Xeraya Capital from Malaysia which is specialised in biotechnology. Xeraya Capital Partner Jason Rushton has been given a seat on the supervisory board of Allecra Therapeutics. Another new investor in the round is BioMedPartners, one of Europe’s largest venture capital investors in the field of healthcare. The Swiss venture capital investor already participated in the first stage of the financing round in which a total of nine million Euros was collected.

Headed up by the M&A specialist Hassan Sohbi, Taylor Wessing had already represented Allecra Therapeutics in the 2016 financing round with a volume of 22 million Euros.

About Allecra Therapeutics

Allecra Therapeutics is a biopharmaceutical company which was established in 2013 with the aim of developing innovative treatments to combat multi-resistant bacterial infections. The company is a member of the BioValley Life Sciences Cluster in the Upper Rhine Valley.

 Legal Advisors

Taylor Wessing: Lead Partner Hassan Sohbi (Partner, Venture Capital, Frankfurt) and Marvin Singh (business lawyer, Venture Capital, Frankfurt)